SomaLogic offers 7,000-plex SomaScan platform as Japan’s first SomaLogic site

SomaLogic announced that Tokyo-based FonesLife Corporation, will be the first SomaLogic Certified Site in Japan. The new site will offer the 7,000-plex SomaScan(R) Assay in their labs and provide SomaScan data to their customers. By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic’s SomaScan Platform-the largest commercially available proteomic platform-and accelerate their own research and provide additional opportunities to utilize the industry-leading platform in the Asia-Pacific region. The SomaLogic Certified Site program gives labs and institutions-including academia and contract research organizations-access to the SomaScan Assay, with more than 7,000 protein measurements per sample and up to 90 samples per assay kit. SOMAmer reagents have been optimized for specificity with specific binding to target epitopes with coefficients of variation of approximately 5 percent, versus polyclonal antibodies that can result in non-specific binding, with CVs as high as 25 percent. "The Certified Sites program allows us to expand the availability of our platform to labs and institutions around the world," said Executive Vice President of SomaLogic’s Life Sciences business, Adam Taich. "Japan is a rapidly growing market for translational work in life sciences and clinical research and we are excited about this opportunity to deepen our long partnership with FonesLife."